Tareq Alsaleh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tareq Alsaleh has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Babu Pappu Mohan
University of Central Florida School of Medicine, Orlando, FL
2 shared publications - John George
Gastroenterology and Hepatology, AdventHealth Orlando
2 shared publications - Mohamad Khaled Almujarkesh
Center for Interventional Endoscopy, AdventHealth, Orlando, FL
2 shared publications - Saurabh Chandan
Advanced Endoscopy, Houston Methodist Hospital, Houston, TX, USA
2 shared publications - Abdullah Abbasi
Center for Interventional Endoscopy (CIE), AdventHealth Orlando, Orlando, FL
1 shared publication - Arisha Rahman
Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication
Latest Publications
- 26 March 2026
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 104 (4) , 548-556.e2
Endoscopic Submucosal Dissection for Locally Recurrent Gastric Neoplasia Following Endoscopic Resection: A Systematic Review and Meta-Analysis
- 26 March 2026
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 104 (4) , 548-556.e2
Endoscopic Submucosal Dissection for Locally Recurrent Gastric Neoplasia Following Endoscopic Resection: A Systematic Review and Meta-Analysis
- Open Access
- 1 November 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (11)
Two Ducts, One Drug—Pembrolizumab-Induced Pancreatic Injury Manifesting as Double-Duct Sign
Immune checkpoint inhibitors (ICIs) can rarely result in ICI-induced pancreatic injury (ICI-PI). Its clinical and radiologic presentation is heterogenous, ranging from asymptomatic radiological signs to severe pancreatitis. Management is mainly with supportive measures and drug discontinuation. In this study, we present an unusual case of ICI-PI, secondary to pembrolizumab, resulting in dilation of both pancreatic and common bile ducts, displaying a “double-duct” sign on imaging. This radiologic sign, commonly associated with malignancy, has not been previously reported with ICI-PI. Endoscopic retrograde cholangiopancreatography with plastic stent placement resulted in quick improvement, highlighting the potential role of endotherapy in treatment of ICI-PI.
- 1 November 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (11)
Open AccessTwo Ducts, One Drug—Pembrolizumab-Induced Pancreatic Injury Manifesting as Double-Duct Sign
Immune checkpoint inhibitors (ICIs) can rarely result in ICI-induced pancreatic injury (ICI-PI). Its clinical and radiologic presentation is heterogenous, ranging from asymptomatic radiological signs to severe pancreatitis. Management is mainly with supportive measures and drug discontinuation. In this study, we present an unusual case of ICI-PI, secondary to pembrolizumab, resulting in dilation of both pancreatic and common bile ducts, displaying a “double-duct” sign on imaging. This radiologic sign, commonly associated with malignancy, has not been previously reported with ICI-PI. Endoscopic retrograde cholangiopancreatography with plastic stent placement resulted in quick improvement, highlighting the potential role of endotherapy in treatment of ICI-PI.